Certara Scientists Featured in List of Top 2% Scientists Worldwide

PRINCETON, N.J.— November 3, 2022 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that eight of the Company’s scientists have been featured in a list of the top 2% of scientists worldwide. The list was published in mid-October 2022 by Elsevier BV and Stanford University. The ranking of scientists worldwide is based on a composite … Continued

Certara’s Simcyp™ Co-Founders receive the 2022 Innovation Award by International Society of Pharmacometrics

ISoP recognizes innovative science and outstanding leadership in the field of Pharmacometrics and related scientific areas PRINCETON, NJ.— November 2, 2022 – Certara, Inc., the global leader in biosimulation, today announced that Amin Rostami, Ph.D and Geoff Tucker, Ph.D., co-founders of Simcyp (now, a division of Certara), have received the 2022 Innovation Award by the … Continued

Certara Announces New Release of PK Submit

PRINCETON, N.J.— October 12, 2022 – Certara, Inc., a global leader in drug development software, today announced the release of the PK Submit™ 2.0. The software allows scientists to automatically create a complete electronic pharmacokinetic (PK) regulatory submission-ready data package within minutes during the normal process of setting up and executing a non-compartmental analysis (NCA). … Continued

Certara Shanghai relocates to a new location and sets sail for a new era

Certara Shanghai relocated the office and held a grand opening ceremony at Hong Kong Plaza in Huangpu District, Shanghai on September 9, 2022. The goal of this move was to provide greater support to local customers  and facilitate meeting market needs. Customers and key opinion leaders in China were invited to the ceremony where they … Continued

Certara to Host Second Annual Symposium Dedicated to Advancing Pediatric Drug Development

PRINCETON, N.J., September 25, 2022 – Certara, a global leader in biosimulation, today announced it will host the second annual New Horizons in Pediatric Drug Development Symposium from October 27-28, 2022. The two-day virtual symposium brings together global thought leaders from academia, industry, patient advocacy organizations and health authorities to discuss the latest innovations in … Continued

Certara Announces Second Year of Fellowship Program in Africa for Applied Pharmacometrics Training

PRINCETON, N.J.— September 25, 2022 — Certara, Inc, a global leader in biosimulation, today announced that it is expanding its Applied Pharmacometrics Training (APT) fellowship program for doctoral-level scientists from Africa, in partnership with Pharmacometrics Africa, CP+ Associates, and other industry and academic partners.  After its successful first year with sixteen fellows, the program has … Continued

IRDiRC Announces Creation of Regulatory Scientific Committee to Tackle Regulatory Challenges in Rare Diseases Research – Press Release

The Rare Disease Research Consortim (IRDiRC) recognizes that rare disease therapeutics and orphan drug development represent unique scientific challenges. We are thrilled to share that Certara’s Senior Director of Regulatory Strategy, Oxana Iliach, PhD. has been elected a member of the newly created Regulatory Science Committee at IRDiRC to help tackle regulatory challenges in rare … Continued

Certara’s Secondary Intelligence™ Software Wins R&D 100 Award

Software that predicts risk of novel drug safety recognized in Software/Services category PRINCETON, NJ – August 25, 2022 – Certara, Inc., a global leader in biosimulation, today announced that its Secondary Intelligence software has won an R&D 100 Award, which recognizes the top 100 “R&D pioneers and their revolutionary ideas in science and technology” each … Continued

Certara Earns 2022 Great Place to Work Certification™

Princeton, NJ, May 17, 2022.  Certara, Inc., a global leader in biosimulation, today announced that the Company was Certified™ by Great Place to Work® in its first year of participation.  The prestigious award is based entirely on what current employees say about their experience working at Certara. This year, 88% of employees said it’s a … Continued

Certara Wins 2022 Edison Award for COVID-19 Vaccine Model

PRINCETON, N.J., May 3, 2022 — Certara, Inc., a global leader in biosimulation, today announced that the Company’s Simcyp COVID-19 Vaccine Model has been awarded a 2022 Bronze Edison Award in the Therapeutic Impact category. The Simcyp COVID-19 Vaccine Model, which is incorporated in Certara’s Vaccine Simulator, uses biosimulation and computer-generated, virtual populations to facilitate … Continued

1 of 3
Powered by Translations.com GlobalLink OneLink Software